UBX-382

• Description :

  UBX-382 is an orally active BTK PROTAC degrader with a DC50 of 4.56 nM. UBX-382 inhibits B-cell receptor signaling by targeting BTK. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins. UBX-382 inhibits tumor growth in murine xenograft models harboring wild-type or C481S mutant BTK-expressing TMD-8 cells. UBX-382 can be used for the study of B-cell-related blood cancers[1].

• UNSPSC :

  12352005

• Target :

  Btk; ERK; MEK; PROTACs; Syk

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway; PROTAC; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ubx-382.html

• Purity :

  96.20

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1C2=CC=C(N3CCC(CC3)CN4CC5=CC(NC6=NC7=C(C(NC8=C(C)C=CC=C8C)=NN7C)C=N6)=CC=C5CC4)C=C2C(N1C9C(NC(CC9)=O)=O)=O

• Molecular Formula :

  C42H44N10O4

• Molecular Weight :

  752.86

• References & Citations :

  [1]Lim YS, et al. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models. Blood Adv. 2023;7 (1) :92-105.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Cereblon

• CAS Number :

  [2884554-45-2]